Oral probiotic combination of Lactobacillus and Bifidobacterium alters the gastrointestinal microbiota during antibiotic treatment for Clostridium difficile infection

被引:35
|
作者
De Wolfe, T. J. [1 ,2 ]
Eggers, S. [3 ]
Barker, A. K. [3 ]
Kates, A. E. [2 ,4 ]
Dill-McFarland, K. A. [5 ]
Suen, G. [5 ]
Safdar, N. [2 ,4 ]
机构
[1] Univ Pittsburgh, Dept Biomed Informat, Pittsburgh, PA 15260 USA
[2] Univ Wisconsin, Sch Med & Publ Hlth, Dept Med, Div Infect Dis, Madison, WI 53706 USA
[3] Univ Wisconsin, Madison Sch Med & Publ Hlth, Dept Populat Hlth Sci, Madison, WI USA
[4] William S Middleton Mem Vet Adm Med Ctr, Madison, WI USA
[5] Univ Wisconsin, Dept Bacteriol, Madison, WI 53706 USA
来源
PLOS ONE | 2018年 / 13卷 / 09期
基金
美国国家卫生研究院; 美国食品与农业研究所;
关键词
FECAL MICROBIOTA; SEQUENCE DATA; RESISTANCE; KEGG;
D O I
10.1371/journal.pone.0204253
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Perturbations in the gastrointestinal microbiome caused by antibiotics are a major risk factor for Clostridium difficile infection (CDI). Probiotics are often recommended to mitigate CDI symptoms; however, there exists only limited evidence showing probiotic efficacy for CDI. Here, we examined changes to the GI microbiota in a study population where probiotic treatment was associated with significantly reduced duration of CDI diarrhea. Subjects being treated with standard of care antibiotics for a primary episode of CDI were randomized to probiotic treatment or placebo for 4 weeks. Probiotic treatment consisted of a daily multi-strain capsule (Lactobacillus acidophilus NCFM, ATCC 700396; Lactobacillus paracasei Lpc-37, ATCC SD5275; Bifidobacterium lactis Bi-07, ATCC SC5220; Bifidobacterium lactis B1-04, ATCC SD5219) containing 1.7 x 10(10) CFUs. Stool was collected and analyzed using 16S rRNA sequencing. Microbiome analysis revealed apparent taxonomic differences between treatments and timepoints. Subjects administered probiotics had reduced Verrucomicrobiaceae at week 8 compared to controls. Bacteroides were significantly reduced between weeks 0 to 4 in probiotic treated subjects. Ruminococcus (family Lachnospiraceae), tended to be more abundant at week 8 than week 4 within the placebo group and at week 8 than week 0 within the probiotic group. Similar to these results, previous studies have associated these taxa with probiotic use and with mitigation of CDI symptoms. Compositional prediction of microbial community function revealed that subjects in the placebo group had microbiomes enriched with the iron complex transport system, while probiotic treated subjects had microbiomes enriched with the antibiotic transport system. Results indicate that probiotic use may impact the microbiome function in the face of a CDI; yet, more sensitive methods with higher resolution are warranted to better elucidate the roles associated with these changes. Continuing studies are needed understand probiotic effects on microbiome structure and function and the resulting impacts on CDI.
引用
收藏
页数:13
相关论文
共 50 条
  • [31] PREDICTORS OF TREATMENT FAILURE IN FECAL MICROBIOTA TRANSPLANT FOR CLOSTRIDIUM DIFFICILE INFECTION
    Stull, Courtney E.
    Fritz, Brandon
    Hardy, Jennifer
    Tabor, Francesca Gutierrez
    Scott, Frank I.
    Freeman, Alison
    GASTROENTEROLOGY, 2019, 156 (06) : S907 - S908
  • [32] Treatment of relapsing Clostridium difficile infection using fecal microbiota transplantation
    Pathak, Rahul
    Enuh, Hill Ambrose
    Patel, Anish
    Wickremesinghe, Prasanna
    CLINICAL AND EXPERIMENTAL GASTROENTEROLOGY, 2014, 7 : 1 - 6
  • [33] Fecal Microbiota Transplant for Treatment of Clostridium difficile Infection in Immunocompromised Patients
    Kelly, Colleen R.
    Ihunnah, Chioma
    Fischer, Monika
    Khoruts, Alexander
    Surawicz, Christina
    Afzali, Anita
    Aroniadis, Olga
    Barto, Amy
    Borody, Thomas
    Giovanelli, Andrea
    Gordon, Shelley
    Gluck, Michael
    Hohmann, Elizabeth L.
    Kao, Dina
    Kao, John Y.
    McQuillen, Daniel P.
    Mellow, Mark
    Rank, Kevin M.
    Rao, Krishna
    Ray, Arnab
    Schwartz, Margot A.
    Singh, Namita
    Stollman, Neil
    Suskind, David L.
    Vindigni, Stephen M.
    Youngster, Ilan
    Brandt, Lawrence
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2014, 109 (07): : 1065 - 1071
  • [34] Probiotic Supplementation in a Clostridium difficile-Infected Gastrointestinal Model Is Associated with Restoring Metabolic Function of Microbiota
    Gaisawat, Mohd Baasir
    MacPherson, Chad W.
    Tremblay, Julien
    Piano, Amanda
    Iskandar, Michele M.
    Tompkins, Thomas A.
    Kubow, Stan
    MICROORGANISMS, 2020, 8 (01)
  • [35] Fecal microbiota transplantation for the treatment of recurrent Clostridium difficile infection.
    Mijares, Jennifer
    Gonzalez-Abreu, Patricia
    Parrish, Shara
    Contreras, Kristina
    PHARMACOTHERAPY, 2016, 36 (12): : E300 - E300
  • [36] Establishing a Fecal Microbiota Transplant Service for the Treatment of Clostridium difficile Infection
    Costello, Samuel P.
    Tucker, Emily C.
    La Brooy, Justin
    Schoeman, Mark N.
    Andrews, Jane M.
    CLINICAL INFECTIOUS DISEASES, 2016, 62 (07) : 908 - 914
  • [37] Encapsulated Lyophilized Fecal Microbiota Therapy for the Treatment of Clostridium difficile Infection
    Borody, Thomas J.
    Mitchell, Scott W.
    Wong, Connie
    Jaworski, Anthony
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2016, 111 : S409 - S409
  • [38] Fecal Microbiota Transplantation for the Treatment of Clostridium difficile Infection A Systematic Review
    Cammarota, Giovanni
    Ianiro, Gianluca
    Gasbarrini, Antonio
    JOURNAL OF CLINICAL GASTROENTEROLOGY, 2014, 48 (08) : 693 - 702
  • [39] Fecal Microbiota Transplantation Use in the Treatment of Recurrent Clostridium difficile Infection
    Parke, Crystal K.
    Norwood, Daryl A.
    Zeitler, Kristen
    Joshi, Ripal
    Gordon, Jamicia
    US PHARMACIST, 2016, 41 (04) : HS22 - HS26
  • [40] Economic Barriers in the Treatment of Clostridium difficile Infection With Oral Vancomycin
    Bunnell, Kristen L.
    Danziger, Larry H.
    Johnson, Stuart
    OPEN FORUM INFECTIOUS DISEASES, 2017, 4 (02):